Avior Wealth Management LLC Has $194,000 Holdings in Illumina, Inc. (NASDAQ:ILMN)

Avior Wealth Management LLC cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 29.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,442 shares of the life sciences company’s stock after selling 1,012 shares during the period. Avior Wealth Management LLC’s holdings in Illumina were worth $194,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. State of Alaska Department of Revenue raised its holdings in shares of Illumina by 2.5% in the 1st quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company’s stock worth $1,469,000 after buying an additional 445 shares in the last quarter. Bender Robert & Associates raised its holdings in shares of Illumina by 12.2% in the 1st quarter. Bender Robert & Associates now owns 39,956 shares of the life sciences company’s stock worth $3,170,000 after buying an additional 4,337 shares in the last quarter. PKO Investment Management Joint Stock Co raised its holdings in shares of Illumina by 133.3% in the 1st quarter. PKO Investment Management Joint Stock Co now owns 3,500 shares of the life sciences company’s stock worth $278,000 after buying an additional 2,000 shares in the last quarter. Rakuten Securities Inc. raised its holdings in shares of Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after buying an additional 270 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its holdings in shares of Illumina by 109.0% in the 1st quarter. Janney Montgomery Scott LLC now owns 18,200 shares of the life sciences company’s stock worth $1,444,000 after buying an additional 9,490 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Illumina

In related news, CFO Ankur Dhingra purchased 6,100 shares of Illumina stock in a transaction dated Monday, May 12th. The shares were acquired at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the transaction, the chief financial officer now directly owns 24,906 shares of the company’s stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.17% of the company’s stock.

Illumina Stock Up 0.1%

Shares of ILMN opened at $90.61 on Tuesday. The firm has a market capitalization of $14.34 billion, a price-to-earnings ratio of -14.93, a PEG ratio of 1.78 and a beta of 1.33. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. The business’s fifty day moving average price is $81.03 and its two-hundred day moving average price is $100.16. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same period last year, the company earned $0.98 EPS. On average, analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ILMN shares. Stephens reissued an “overweight” rating and issued a $105.00 target price on shares of Illumina in a report on Tuesday, May 20th. Robert W. Baird decreased their price target on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. HSBC lowered Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. Morgan Stanley decreased their price target on Illumina from $136.00 to $100.00 and set an “equal weight” rating on the stock in a research report on Monday, May 12th. Finally, Guggenheim decreased their price target on Illumina from $122.00 to $114.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina has an average rating of “Moderate Buy” and a consensus price target of $126.94.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.